Health Dictionary Find a Doctor

Struma ovarii screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]

Overview

Overview

There is insufficient evidence to recommend routine screening for Struma ovarii. However, in cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease.

Screening

Screening

References

References

  1. Volpi E, Ferrero A, Nasi PG, Sismondi P (2003). “Malignant struma ovarii: a case report of laparoscopic management”. Gynecol. Oncol. 90 (1): 191–4. PMID 12821363.
  2. Zekri JM, Manifold IH, Wadsley JC (2006). “Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments”. Clin Oncol (R Coll Radiol). 18 (10): 768–72. PMID 17168212.
  3. Sinha NK (2014). “Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary”. J Clin Diagn Res. 8 (3): 140–1. doi:10.7860/JCDR/2014/8005.4138. PMC 4003614. PMID 24783110.
  4. Balci TA, Kabasakal L (2005). “Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?”. Gynecol. Oncol. 99 (2): 520. doi:10.1016/j.ygyno.2005.04.017. PMID 15963556.
  5. McGill JF, Sturgeon C, Angelos P (2009). “Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation”. Endocr Pract. 15 (2): 167–73. doi:10.4158/EP.15.2.167. PMID 19289330.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH